BCR–ABL1T315I mutation, a negative prognostic factor for the terminal phase of chronic myelogenous leukemia treated with first- and second-line tyrosine kinase inhibitors, might be an indicator of allogeneic stem cell transplant as the treatment of choice

  • Ciprian Tomuleasa, Delia Dima, Ioana Frinc, Mariana Patiu, Bobe Petrushev, Andrei Cucuianu, Ioana Berindan-Neagoe
  • Leukemia & Lymphoma, August 2014, Taylor & Francis
  • DOI: 10.3109/10428194.2014.940582

The authors haven't finished explaining this publication. If you are the author, sign in to claim or explain your work.

Read Publication

http://dx.doi.org/10.3109/10428194.2014.940582

The following have contributed to this page: Professor Berindan Neagoe I Ioana